TKT and chronic myelogenous leukemia, BCR-ABL1 positive: Ponatinib is a multitargeted TK inhibitor, particularly active as pan-Bcr-Abl inhibitor and for this activity it has been approved by FDA and EMA for the treatment of Ph+ leukemias, especially CML, resistant to prior therapies.